Clinical factors associated with bacterial translocation in Japanese patients with type 2 diabetes: A retrospective study

Dipeptidyl-4 (DPP-4) inhibitors are oral antidiabetic agents recently introduced to Malaysia. Thus, limited data is available on their utilization patterns and factors associated with their use. This study aims to analyse the utilization patterns of DPP-4 inhibitors, factors that influenced the choice of agent, and the rationale for treatment with DPP-4 inhibitors in patients with type 2 diabetes mellitus. This retrospective study was conducted to address the utilization pattern of DPP-4 inhibitors and factors that influence choice in type 2 diabetes mellitus patients. 299 subjects taking either sitagliptin or vildagliptin from September 2008 to September 2012 were included in the study. Sitagliptin was more frequently prescribed than vildagliptin. Of the patients prescribed DPP-4 inhibitors, 95% received combinations of these and other agents, whereas only 5% were prescribed DPP-4 inhibitors as monotherapy. Factors affecting the utilization of DPP-4 inhibitors included age(P=0.049)and concomitant use of beta blockers(P=0.045)and aspirin(P=0.008). Early identification of factors associated with DPP-4 inhibitors is essential to enhance quality use of the drugs.

Download Full-text

Clinical Factors Associated with Initial Decrease in Body-Fat Percentage Induced by Add-on Sodium-Glucose Co-transporter 2 Inhibitors in Patient with Type 2 Diabetes Mellitus

Clinical Drug Investigation ◽

10.1007/s40261-017-0580-6 ◽

2017 ◽

Vol 38 (1) ◽

pp. 19-27 ◽

Cited By ~ 9

Author(s):

Noboru Kurinami ◽

Seigo Sugiyama ◽

Hiroyuki Nishimura ◽

Ayami Morita ◽

Akira Yoshida ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Body Fat ◽

Body Fat Percentage ◽

Clinical Factors ◽

Fat Percentage ◽

Factors Associated ◽

Initial Decrease

Download Full-text

Depression and Diabetes: A large population-based study of sociodemographic, lifestyle, and clinical factors associated with depression in type 1 and type 2 diabetes

Diabetes Care ◽

10.2337/diacare.28.8.1904 ◽

2005 ◽

Vol 28 (8) ◽

pp. 1904-1909 ◽

Cited By ~ 107

Author(s):

A. Engum ◽

A. Mykletun ◽

K. Midthjell ◽

A. Holen ◽

A. A. Dahl

Keyword(s):

Type 2 Diabetes ◽

Large Population ◽

Population Based ◽

Clinical Factors ◽

Population Based Study ◽

Factors Associated

Download Full-text

Clinical factors associated with the occurrence of nausea and vomiting in type 2 diabetes patients treated with glucagon-like peptide-1 receptor agonists

Journal of Diabetes Investigation ◽

10.1111/jdi.12900 ◽

2018 ◽

Vol 10 (2) ◽

pp. 408-417

Author(s):

Megumi Shiomi ◽

Tesshu Takada ◽

Yoichi Tanaka ◽

Keiko Yajima ◽

Akira Isomoto ◽

...

Keyword(s):

Type 2 Diabetes ◽

Nausea And Vomiting ◽

Clinical Factors ◽

Factors Associated ◽

Receptor Agonists ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1 ◽

Diabetes Patients

Download Full-text

Clinical Factors Associated with High Glycemic Variability Defined by Coefficient of Variation in Patients with Type 2 Diabetes

Medical Devices Evidence and Research ◽

10.2147/mder.s288526 ◽

2021 ◽

Vol Volume 14 ◽

pp. 97-103

Author(s):

AM Gómez ◽

DC Henao-Carillo ◽

L Taboada ◽

O Fuentes ◽

O Lucero ◽

...

Keyword(s):

Type 2 Diabetes ◽

Coefficient Of Variation ◽

Glycemic Variability ◽

Clinical Factors ◽

Factors Associated

Download Full-text

Real-world risk of hypoglycemia-related hospitalization in Japanese patients with type 2 diabetes using SGLT2 inhibitors: a nationwide cohort study

BMJ Open Diabetes Research & Care ◽

10.1136/bmjdrc-2020-001856 ◽

2020 ◽

Vol 8 (2) ◽

pp. e001856

Author(s):

Takeshi Horii ◽

Yoichi Oikawa ◽

Narumi Kunisada ◽

Akira Shimada ◽

Koichiro Atsuda

Keyword(s):

Type 2 Diabetes ◽

Cohort Study ◽

Real World ◽

Sglt2 Inhibitor ◽

Japanese Patients ◽

Sglt2 Inhibitors ◽

Clinical Factors ◽

Glucose Levels ◽

Increased Risk

IntroductionSodium-glucose cotransporter 2 (SGLT2) inhibitors are believed to lower glucose levels and inhibit cardiovascular events related to type 2 diabetes (T2D). To maximize their benefits, the risk of resultant hypoglycemia has to be minimized; however, the magnitude of this risk remains unclear. Here, we aimed to identify clinical factors linked to an increased risk of hypoglycemia among Japanese patients with T2D and treated with SGLT2 inhibitors.Research design and methodsThis was a real-world retrospective cohort study conducted using the Japanese Medical Data Vision database. We identified patients with T2D and treated with SGLT2 inhibitors who were enrolled in the database from April 2014 to October 2019. Cox multivariate regression analyses were performed to determine demographical and clinical factors linked to SGLT2 inhibitor-associated hypoglycemia-related hospitalization.ResultsOf 171 622 patients prescribed SGLT2 inhibitors, hypoglycemia-related hospitalization occurred in 216 (0.13%), with 0.60 incidences per 100 person-years. The risk of SGLT2 inhibitor-associated hypoglycemia was higher with each 10-year increase in age (HR 1.49; 95% CI 1.32 to 1.68) and high in patients with body mass index <25 kg/m2 (HR 1.98; 95% CI 1.50 to 2.61), insulin use (HR 3.26; 95% CI 2.43 to 4.38), and sulfonylurea use (HR 1.44; 95% CI 1.02 to 2.03). The risk was lower in women than in men (HR 0.73; 95% CI 0.54 to 0.98) and low in concomitant metformin users (HR 0.52; 95% CI 0.37 to 0.74).ConclusionsThese findings may help minimize the risk of hypoglycemia-related hospitalization due to T2D treatment with SGLT2 inhibitors. We revealed that the risk of hypoglycemia may be higher when combining SGLT2 inhibitors with sulfonylureas and/or insulin. Furthermore, we discovered a high risk of hypoglycemia in older and non-obese patients. These findings may assist in maximizing the benefits of SGLT2 inhibitors for the treatment of T2D.

Download Full-text